Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors (Journal of Experimental & Clinical Cancer Research, (2023), 42, 1, (76), 10.1186/s13046-023-02649-6)

Following publication of the original article [1], an error was identified in Fig. 2, specifically: Fig. 2b - CL/F (mL/hr) needs to be corrected in CL/F (L/hr) Furthermore, two Supplementary Materials should also be uploaded. The added Supplementary Materials are: Additional file 7: Supplementary Materials and Methods. Additional file 8: NEO-201 protocol. This modification does not affect the integrity of the results. Clinical Pharmacokinetics of NEO-201 A. NEO-201 serum concentrations averaged for each dose level and plotted over time. B. Noncompartmental analysis of first dose of NEO-201 including the mean estimates for relevant PK parameters during dense PK sampling following the first dose given on C1D1. *Data presented as arithmetic means (%CV) due to low numbers in each group. ¹ Two patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. ² One patient had insufficient terminal data to accurately estimate a half-life, thus clearance and volume too. ³ Four patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. ⁴ One patient had insufficient terminal data to accurately estimate a half-life, thus clearance and volume too. ⁵ Two patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. C. Individual NEO-201 serum concentration–time profiles of 1.0 mg/kg cohort. D-E. Individual NEO-201 serum concentration–time profiles of patients in 1.5 mg/kg cohort (D) and 2.0 mg/kg cohort (E). F-G. Differences in NEO-201 distribution volume by sex (F) and body size (G).